{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:14Z","timestamp":1777564574415,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejca.2022.07.009","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T06:04:58Z","timestamp":1660284298000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-3665","authenticated-orcid":false,"given":"Gabriele","family":"Antonarelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0267","authenticated-orcid":false,"given":"Chiara","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-0743","authenticated-orcid":false,"given":"Sara","family":"Manglaviti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-5841","authenticated-orcid":false,"given":"Gianluca Maria","family":"Varano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piermario","family":"Salvini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5684-5254","authenticated-orcid":false,"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.07.009_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ctrv.2018.10.001","article-title":"Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)","volume":"71","author":"Imbimbo","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.009_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jtcvs.2020.10.131","article-title":"The eighth edition TNM stage classification for thymic tumors: what do I need to know?","volume":"161","author":"Ahmad","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.009_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2019.11.013","article-title":"The international association for the study of lung cancer thymic tumors staging project: the impact of the eighth edition of the union for international cancer control and American Joint Committee on cancer TNM stage classification of thymic tumors","volume":"15","author":"Ruffini","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.009_bib4","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.21037\/tlcr-20-1222","article-title":"Narrative review of immunotherapy in thymic malignancies","volume":"10","author":"Benitez","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.009_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.009_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.009_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"20","key":"10.1016\/j.ejca.2022.07.009_bib8","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.009_bib9","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.009_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.009_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.07.009_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.07.009_bib13","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.2147\/OTT.S101385","article-title":"Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives","volume":"9","author":"Mulet-Margalef","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.009_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/annonc\/mdp291","article-title":"Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib","volume":"21","author":"Blay","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.009_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"25","key":"10.1016\/j.ejca.2022.07.009_bib16","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.009_bib17","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","article-title":"RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial","volume":"26","author":"Lee","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.009_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/annonc\/mdv589","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis","volume":"27","author":"Bracarda","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.009_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cncr.26440","article-title":"Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma","volume":"118","author":"Barrios","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.009_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"10.1016\/j.ejca.2022.07.009_bib21","article-title":"Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST","volume":"25","author":"George","year":"2007","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.009_bib22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:21Z","timestamp":1760733381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":22,"alternative-id":["S0959804922004300"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}